FY 2023 GPRA/GPRAMA IDCS National Results

INDIAN HEALTH SERVICE (IHS) GPRA PERFORMANCE RESULTS

Introduction

Beginning with FY 2018, IHS clinical GPRA results are calculated from the Integrated Data Collection System (IDCS), a data mart within the National Data Warehouse (NDW) General Data Mart. Service unit/health program data is exported to the NDW by reporting sites for inclusion in GPRA results.

The measure logic is programmed centrally within the IDCS data mart and mimics the CRS measure logic, which is located here

Each clinical measure has two graphs:

- IHS national performance result and historical data
- IHS Area graphs comparing the current reporting year to the previous year for each of IHS's twelve Area Offices.
- FY 2023 and FY 2022 National results include data from IHS, Tribal, and Urban Indian health programs. Prior to FY 2018 urban results were posted separately.

Area Abbreviations

Abbreviation	Area
ALA	Alaska
ALB	Albuquerque
BEM	Bemidji
BIL	Billings
CAL	California
GPA	Great Plains
NAS	Nashville
NAV	Navajo
OKL	Oklahoma
PHX	Phoenix
POR	Portland
TUC	Tucson

Measure Acronym Definitions

Acronym	Definition
A1c	Hemoglobin A1c
AI/AN	American Indian/Alaska Native
ВМІ	Body Mass Index
ВР	Blood Pressure
CHD	Coronary Heart Disease
CVD	Cardiovascular Disease
DV/IPV	Domestic Violence/Intimate Partner Violence
HIV	Human Immunodeficiency Virus
НР	Healthy People
IDCS	Integrated Data Collection System
IHD	Ischemic Heart Disease
LDL	Low Density Lipoprotein
MH	Million Hearts
NDW	National Data Warehouse
NPIRS	National Patient Information Reporting System
SBIRT	Screening, Brief Intervention, & Referral to Treatment

GPRA 2023 Results Summary

Of the 26 measures that IHS/Tribal/Urban programs reported in FY 2023:

- 18 measures improved over FY 2022 results
- 6 measures decreased in performance from FY 2022 results
- 2 measures were not comparable to FY 2022 results due to logic changes
- 17 measures met or exceeded FY 2023 targets, including 2 measures with "Baseline" targets
- 9 measures did not meet FY 2023 targets
- The DV/IPV GPRAMA measure did not meet the 2023 target
- The Influenza Vaccination 18+ GPRAMA measure did meet the 2023 target

In FY 2023, 18 measures improved over FY 2022 performance

Measure	FY 2022	FY 2023	Difference
Mammography Screening	29.2%	38.4%	9.2%
Topical Fluoride	20.9%	25.6%	4.7%
Retinopathy Exam	41.8%	45.2%	3.4%
Dental: General Access	22.3%	25.3%	3.0%
Breastfeeding Rates	39.3%	41.8%	2.5%
HIV Screening Ever	38.0%	40.3%	2.3%
Sealants	9.0%	11.0%	2.0%
Depression Screening 12-17 yrs	32.1%	34.1%	2.0%
Diabetes: Controlled BP	53.0%	54.6%	1.6%
Nephropathy Assessed	41.0%	42.5%	1.5%

In FY 2023, 18 measures improved over FY 2022 performance (continued):

Measure	FY 2022	FY 2023	Difference
Poor Glycemic Control	14.6%	13.2%	1.4%
Tobacco Cessation	25.0%	26.1%	1.1%
Universal Alcohol Screening	33.2%	34.2%	1.0%
Childhood Weight Control	23.0%	22.0%	1.0%
DV/IPV Screening	28.3%	28.9%	0.6%
Cervical Cancer Screening	33.2%	33.8%	0.6%
Depression Screening 18 yrs and older	37.0%	37.4%	0.4%
Controlling High BP (MH)	45.5%	45.7%	0.2%

In FY 2023, 6 measures decreased in performance from FY 2022:


Measure	FY 2022	FY 2023	Difference
Statin Therapy	58.5%	49.9%	-8.6%
CVD Statin Therapy	42.7%	35.0%	-7.7%
Influenza Vaccination 6mo - 17 yrs	18.5%	17.4%	-1.1%
Colorectal Cancer Screening	23.7%	23.3%	-0.4%
Childhood IZ	36.1%	35.9%	-0.2%
Influenza Vaccination 18+	20.0%	19.9%	-0.1%

In FY 2023, 2 measures had logic changes and were not comparable to FY 2022 results:

Measure	FY 2023	Target
Adult Immunizations	37.0%	Baseline
SBIRT	15.0%	Baseline


Diabetes: Poor Glycemic Control

AI/AN patients with diabetes who have had Poor A1c control (>9) during the past year.




^{*}New measure in FY 2019

Diabetes: Poor Glycemic Control




Diabetes: Blood Pressure Control

AI/AN patients with diabetes who have maintained BP control (<140/90) during the past year.




Diabetes: Blood Pressure Control (<140/90)




Diabetes: Statin Therapy to Prevent Cardiovascular Disease Risk

AI/AN patients with diabetes who are statin therapy users or receive a prescription for statin therapy during the report period.




Diabetes: Statin Therapy to Prevent CVD Risk




Diabetes: Nephropathy Assessment

AI/AN patients with diabetes who have been assessed for nephropathy within the past year.




Diabetes: Nephropathy Assessment




Diabetes: Retinopathy

AI/AN patients with diabetes who have been assessed for retinopathy within the past year.




Diabetes: Retinopathy




Dental: General Access

AI/AN patients who have received dental services within the past year.




Dental: General Access




Dental: Sealants

AI/AN children with intact dental sealants.




Dental: Sealants




Dental: Topical Fluorides

AI/AN children with at least one topical fluoride treatment within the past year.




stPrior to FY 2013, this measure tracked the number of patients receiving one or more fluoride applications in the past year

Dental: Topical Fluorides




Immunizations: Influenza 6mo - 17yrs

AI/AN patients (ages 6 months to 17 years) who have received the influenza vaccine within the past year.




Immunizations: Influenza 6mo – 17yr




Immunizations: Influenza 18+

AI/AN patients (ages 18+) who have received the influenza vaccine within the past year.




Immunizations: Influenza 18+




Immunizations: Adult Immunizations

AI/AN patients (age 19+) who have received all age-appropriate immunization combinations.




*In FY 2023, age ranges for recommended vaccines were updated, as were vaccines included in measure logic

Adult Immunizations




Immunizations: Childhood (19-35 months)

AI/AN patients (age 19-35 months) who have received the combined childhood vaccination series (4:3:1:3*:3:1:4).




Immunizations: Childhood (19-35 months)




Cervical Cancer Screening

AI/AN women age 24-64 who have received a Pap screen within the previous three years, or age 30-64 years with a Pap screen in the past three years or a Pap Screen and an HPV DNA documented on the same day in the past five years.




*Prior to FY 2022, HPV Primary in the past five years was not included in the measure logic

Cervical Cancer Screening




Cancer Screening: Breast (Mammography)

AI/AN women (age 52-74) who have received mammography screening within the previous two years.




*Prior to FY 2019, measure tracked women ages 52-64 years

Cancer Screening: Breast (Mammography)




Cancer Screening: Colorectal

AI/AN patients ages 45-75 who have received appropriate Colorectal Cancer Screening.




*Prior to FY 2022, measure included patients ages 50-75 years in the denominator

Cancer Screening: Colorectal




Tobacco Cessation

AI/AN tobacco-using patients who have received tobacco cessation intervention within the past year or quit their tobacco use within the past year.




Tobacco Cessation




Universal Alcohol Screening

AI/AN patients ages 9-75 who have been screened for alcohol use within the past year.




Universal Alcohol Screening




Screening, Brief Intervention, Referral to Treatment (SBIRT)

AI/AN patients ages 9-75 who screened positive for alcohol use and were provided a brief intervention or brief negotiated interview within seven days of the positive screen




*Prior to FY 2023, telemedicine visits were not included in measure logic

SBIRT




Domestic Violence/Intimate Partner Violence Screening:

AI/AN women (age 14-46) who were screened for domestic violence /intimate partner violence within the past year.




DV/IPV Screening




Depression Screening 12-17

AI/AN patients ages 12-17 who have been screened for depression or diagnosed with a mood disorder within the past year.




Depression Screening 12 – 17 years




Depression Screening 18+


AI/AN patients ages 18 and older who have been screened for depression or diagnosed with a mood disorder within the past year.




Depression Screening 18+




Childhood Weight Control (CWC)
AI/AN children ages 2-5 years with a BMI at or above 95th percentile.




Childhood Weight Control



HIV Screening Ever
AI/AN patients who have ever received screening for HIV.




HIV Screening Ever




CVD Statin Therapy

Patients age 40 to 75 with diabetes, or patients of any age with documented ASCVD or patients age 20 and older with an LDL greater than or equal to 190 or an active diagnosis of familial hypercholesterolemia who are statin therapy users




CVD Statin Therapy




Controlling High Blood Pressure (MH)

AI/AN patients with diagnosed hypertension who have achieved blood pressure control (<140/90).




^{*}Measure logic change in FY 2019.

Controlling High Blood Pressure (MH)




Breastfeeding Rates

AI/AN patients who, at the age of two months, were either exclusively or mostly breastfed.



Breastfeeding Rates



FY 2023 National Dashboard (IHS/Tribal/Urban)				
DIABETES	FY 2022 Target	FY 2022 Final	FY 2023 Target	FY 2023 Final	FY 2023 Final Result
Poor Glycemic Control	15.6%	14.6%	14.4%	13.2%	Met
Controlled BP <140/90	57.0%	53.0%	52.4%	54.6%	Met
Statin Therapy	56.8%	58.5%	54.5%	49.9%	Not Met
Nephropathy Assessed	43.7%	41.0%	45.1%	42.5%	Not Met
Retinopathy Exam	41.2%	41.8%	44.7%	45.2%	Met
DENTAL					
Dental: General Access	28.8%	22.3%	24.4%	25.3%	Met
Sealants	13.7%	9.0%	9.9%	11.0%	Met
Topical Fluoride	26.8%	20.9%	21.1%	25.6%	Met
IMMUNIZATIONS					
Influenza Vaccination 6mo - 17yrs	29.7%	18.5%	19.8%	17.4%	Not Met
Influenza Vaccination 18+	28.0%	20.0%	19.7%	19.9%	Met
Adult Immunizations ¹	44.4%	36.1%	Set Baseline	37.0%	Met
Childhood IZ	47.8%	36.1%	40.9%	35.9%	Not Met
PREVENTION					
Cervical Cancer Screening ²	Set Baseline	33.2%	33.2%	33.8%	Met
Mammography Screening	39.7%	29.2%	28.7%	38.4%	Met
Colorectal Cancer Screening ²	Set Baseline	23.7%	23.7%	23.3%	Not Met
Tobacco Cessation	29.8%	25.0%	24.4%	26.1%	Met
Universal Alcohol Screening	39.2%	33.2%	32.2%	34.2%	Met
SBIRT ¹	13.5%	14.3%	Set Baseline	15.0%	Met
IPV/DV Screening	36.3%	28.3%	29.6%	28.9%	Not Met
Depression Screening 12 - 17 years	33.9%	32.1%	29.5%	34.1%	Met
Depression Screening 18+	42.9%	37.0%	36.4%	37.4%	Met
Childhood Weight Control ³	22.6%	23.0%	22.6%	22.0%	Met

45.5%

42.7%

38.0%

39.3%

45.8%

37.8%

38.9%

42.6%

45.7%

35.0%

40.3%

41.8%

Controlling High Blood Pressure (MH)

CVD Statin Therapy

Breastfeeding Rates

HIV Screen Ever

FY 2023 Measures Met: 17

Not Met

Not Met

Met

Not Met

40.9%

40.6%

38.0%

42.0%

Measures in red font are GPRAMA measures.

FY 2023 Measures Not Met: 9

¹ Measure logic change beginning in FY 2023

² Measure logic change beginning in FY 2022 and measure name change from "(Cervical) Pap Screening" to "Cervical Cancer Screening"

³ Long term measure, FY 2021 is the official report year. FY 2022 and FY 2023 lists FY 2021 target, next report year is FY 2024.